Anti-ageing Dermal Agent Using Adenosine N1-oxide 5'-phosphate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-ageing external dermal agents are limited in their ability to effectively improve skin turnover, maintain barrier function, and prevent wrinkles, fine wrinkles, and spots, as they primarily focus on a few mechanisms and have challenges with handleability and production feasibility.
Innovation Solution
The use of adenosine N1-oxide 5′-phosphates, their analogs, and salts, combined with ascorbic acid 2-glucoside, epigallocatechin gallate, and EDTA, which enhance skin turnover, maintain or accelerate elastin production, inhibit matrix metalloproteinase-1 and endothelin-1 production, and improve the skin barrier function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-ageing agents are used, then some skin improvements are achieved, but the ability to effectively improve skin turnover and maintain barrier function is limited
Solution Approach 1:
The patent combines multiple active ingredients (adenosine N1-oxide 5'-phosphate, ascorbic acid 2-glucoside, epigallocatechin gallate, and EDTA) into a single external dermal agent formulation. This merging of multiple mechanisms (turnover enhancement, barrier function maintenance, elastin production acceleration, and MMP-1 inhibition) into one comprehensive product resolves the contradiction by providing broad anti-ageing coverage while maintaining effective delivery of each component
Solution Approach 2:
The external dermal agent is designed to perform multiple functions simultaneously: enhancing skin turnover, maintaining barrier function, accelerating elastin production, and inhibiting MMP-1. This multi-functional formulation addresses various ageing mechanisms at once, improving both reliability and adaptability of the anti-ageing treatment
2Reliability
If multiple ingredients are combined to enhance anti-ageing effects, then effectiveness improves, but handleability and production feasibility become challenging
Solution Approach 1:
The patent specifies precise concentration ranges for each ingredient (adenosine N1-oxide 5'-phosphate: 0.001-10%, ascorbic acid 2-glucoside: 0.1-10%, epigallocatechin gallate: 0.01-5%, EDTA: 0.01-1%) to optimize both effectiveness and manufacturability. By defining these parameter ranges, the patent balances high anti-ageing performance with practical production feasibility, allowing manufacturers to produce the formulation within controlled specifications
3Object-affected harmful factors
If skin turnover is accelerated to prevent wrinkles, then wrinkle prevention improves, but skin barrier function may be compromised
Solution Approach 1:
The patent combines turnover-enhancing ingredients (adenosine N1-oxide 5'-phosphate) with barrier-protective ingredients (ascorbic acid 2-glucoside and epigallocatechin gallate) in the same formulation. This merging ensures that while skin turnover is accelerated to prevent wrinkles, the barrier function is simultaneously maintained through the protective actions of the other components, resolving the contradiction between wrinkle prevention and barrier maintenance
Data Source
AI summary
The present invention aims to provide an external dermal composition for anti-ageing, which prevents or improves apparent skin problems such as age-related or senescent wrinkles, fine wrinkles, saggings, spots, etc., as well as maintaining or enhancing the skin barrier functions. The object is solved by providing an external dermal agent for anti-ageing, which contains as an effective ingredient(s) one or more members selected from the group consisting of adenosine N1-oxide 5′-phosphate, analogs thereof, and their salts.